Investment Bankers for the
Life Sciences Industry

BroadOak Partners advises Lucigen Corporation on the sale of the company to LGC Limited. Lucigen is a leading provider of molecular biology enzymes, reagents, and kits for high growth…

BroadOak Partners advises Linkage Biosciences on the sale of the company to Thermo Fisher Scientific. Linkage Biosciences is a provider of molecular…

BroadOak Partners advises Trinean on the sale of the company to Unchained Labs. Trinean is a provider of instrumentation and analytical software…

BroadOak Partners acted as the exclusive placement agent for LabConnect’s $24.5 million Series A financing…

BroadOak Partners advises Rubicon Genomics on the sale of the company to Takara Bio. Rubicon Genomics is a provider high quality, nucleic acid library…

BroadOak Partners advises MTI-GlobalStem on the sale of the company to Thermo Fisher Scientific Inc. MTI-GlobalStem is a provider of leading-edge technology and reagents for…

BioCision, LLC, a BroadOak portfolio company, has divested its Cool Lab subsidiary to Brooks Automation, Inc. (Nasdaq:BRKS). Cool Lab, LLC provides…

BroadOak portfolio company, BioCision, LLC announces the formation of MedCision Inc, an independent company focused on the automation of pre-clinical and clinical…

BroadOak provided growth capital financing to antibodies-online GmbH, a leading digital marketing and e-commerce platform for the distribution of life sciences research products…

BroadOak Partners advises Maravai LifeSciences, Inc., a partnership including GTCR, a leading private equity firm…

BroadOak Partners advises Bioo Scientific Corporation on the sale of the company to PerkinElmer, Inc. Bioo Scientific is a leading provider of food safety tests sold into food…

BroadOak Partners advises Clarity Medical Systems, a leading provider of clinical ophthalmic technologies, on the…

BroadOak Partners advises Maravai LifeSciences, Inc., a partnership including GTCR, a leading private equity firm,…

The BroadOak Fund III has completed a $4.0 million investment into LabConnect, LLC, a leading global provider of central…

BroadOak Partners advises AdvanDx, a developer of rapid molecular tests for the diagnosis and treatment of…

BroadOak Capital Partners led the round, joined by Research Corporation Technologies. The Ann Arbor, Michigan-based…

The BroadOak Fund, an affiliate of BroadOak Capital Partners, provided financing to Diagnostic Biosystems to support…

BroadOak Capital Partners, through its affiliate the BroadOak Fund, successfully exited its investment in Spectra Analysis Instruments, Inc. upon sale…

BroadOak Capital Partners, through its affiliate the BroadOak Fund, lead a $3.0 million financing for Orflo Technologies, an innovator of cell analysis…

The BroadOak Fund, an affiliate of BroadOak Capital Partners, provided financing to BioInformatics for the acquisition of Strategic Directions International, Inc.…

BroadOak Partners advises Stemgent, a leader in developing innovative technology and application solutions that provide researchers the tools to investigate and understand cellular…

BroadOak Partners advises Asuragen, a molecular diagnostics company, on the sale of its miRInform Thyroid™ and Pancreas tests to PDI, Inc.’s subsidiary, Interpace Diagnostics.

BroadOak Partners advises Edge Biosystems, a specialized manufacturer and distributor of sample preparation and clean-up products for use in DNA sequencing, on its sale to StoneCalibre.

BroadOak Partners advises BioCision in a strategic investment by Brooks Automation to accelerate commercial momentum. In addition, the companies entered into a collaboration agreement to jointly develop products that support transport, storage and processing of biomaterials.

BroadOak Partners advises Advanced Bioscience Laboratories (“ABL”), a leading life science contract research and manufacturing organization, on the sale of its in-vivo preclinical business to BIOQUAL, Inc.

BroadOak Partners advises EdgeBio, a research reagents and sequencing services company, on the sale of its genetic sequencing services business to BioReference Laboratories, Inc.

BroadOak Partners advises SDIX, an antibody focused biotechnology company, on the sale of the assets of its Life Science business to OriGene Technologies, Inc. for $16 million. BroadOak Partners also rendered a fairness opinion to the board of directors of SDIX.

BroadOak Partners advises UVP LLC on the sale of the company to Analytik Jena AG.  UVP is a leading developer and manufacturer of bioimaging systems and ultraviolet products for the academic, pharmaceutical and biotechnology markets and a portfolio company of Carlyle Enterprises.

BroadOak Partners advises SeraCare Life Sciences, a diagnostics products company, on the sale of its BioServices business, a division which provides biorepository and sample handling services, to Precision Bioservices, Inc.

BroadOak Partners advises SDIX, an antibody focused biotechnology company, on the sale of its Food Safety and GMO businesses to Romer Labs.

BroadOak Partners advises Carestream Health, Inc., a leader in healthcare imaging systems and films, on the sale of the in vivo business of Carestream Molecular Imaging, a division which provides preclinical…

BroadOak Capital Partners, through its affiliate the BroadOak Fund, participated in a financing for BioCision, LLC, a bench-top laboratory tools provider, to help fund the company’s growth.